Clinical trials are essential in improving treatment in the world of oncology, especially for rare cancers.
Ghassan Abou-Alfa, M.D., a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the basics of clinical trials, and why participation in them is important.
Clinical trials play a vital role in moving the field of oncology forward. They assesses the safety of a drug, how effective it is in treating the disease and how it works compared to the current standard of care. Since some rarer cancers — like fibrolamellar cancer – do not have standards of care, phase 1 and phase 2 trials will suffice, and patient participation can be even more important.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More